

SPONSORSHIP AGREEMENT

This Sponsorship Agreement (“**Agreement**”) is entered into as of the date the last signature to the contract (“**Effective Date**”) by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark (“**Novartis**”) and **HudSagen/Patientforeningen HS Danmark** an Organization incorporated under the laws of Denmark, located at Handicaporganisationernes Hus, Blekinge Boulevard 2, DK-2630 Taastrup, (“**Sponsorship Recipient**”). Novartis and Sponsorship Recipient may hereinafter be referred to individually as a “**Party**” and collectively as the “**Parties**”.

WHEREAS, Sponsorship Recipient has specifically requested Novartis’ financial contribution to support the Sponsorship Activity (as defined in Exhibit A), through a Sponsorship Request Letter, which is attached hereto as Exhibit B:

WHEREAS, in accordance with the Sponsorship Request Letter mentioned above, Novartis wishes to support the Sponsorship Activity with the Sponsorship Amount (as defined in Exhibit A),

WHEREAS, Novartis will receive a tangible benefit in connection with the sponsorship (as defined in Exhibit A); and,

WHEREAS, Sponsorship Recipient accepts the Sponsorship Amount subject to the terms and conditions of this Agreement,

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. SPONSORSHIP BY NOVARTIS

- 1.1 **Sponsorship.** Novartis will provide the Sponsorship Amount as set forth in Exhibit A solely to support Sponsorship Recipient in performing the Sponsorship Activity as set forth in Exhibit A.
- 1.2 **Tangible benefit.** Novartis will receive a tangible benefit as set forth in Exhibit A.
- 1.3 **Statement of Purpose.** The Sponsorship Activity is for: **HudSagens aktiviteter i 2025.**
- 1.4 **Novartis Responsibility.** Sponsorship Recipient agrees that Novartis’ responsibility is solely to provide the Sponsorship Amount and to receive the tangible benefit. Novartis will not be liable to Sponsorship Recipient or to any other person for the Sponsorship Activity or the use of the Sponsorship Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Sponsorship Recipient to return the Sponsorship Amount and take other corrective action if Sponsorship Recipient breaches this Agreement.

2. OBLIGATIONS OF SPONSORSHIP RECIPIENT

- 2.1 **Use of Sponsorship Amount.**

- (a) Sponsorship Recipient shall use the Sponsorship Amount solely for the Sponsorship Activity and shall not use the Sponsorship Amount for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Sponsorship Recipient undertakes to independently contact Novartis in the event any part of the Sponsorship Amount has not been used for the Sponsorship Activity so that such amount can be refunded to Novartis without undue delay.
- (b) Sponsorship Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Sponsorship Activity. Sponsorship Recipient warrants that the Sponsorship Activity is compliant with all such requirements.
- (c) Sponsorship Recipient is solely responsible because the Sponsorship Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Sponsorship Activity and the use of the Sponsorship Amount. Any claims for payment from third parties involved in the Sponsorship Activity are the sole responsibility of Sponsorship Recipient and Novartis will not fund any additional amounts for the Sponsorship Activity.

2.2 **Objectivity & Balance.**

- (a) The Sponsorship Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Sponsorship Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Sponsorship Activity will include a discussion of multiple treatment options and will not focus on a single product.
- (c) Sponsorship Recipient will ensure that any titles or overview information relating to the Sponsorship Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Sponsorship Recipient is responsible for selection of presenters, moderators and collaborators for the Sponsorship Activity. Novartis will not control the planning, content, speaker selection or execution of any Sponsorship Activity. If Novartis suggests presenters, moderators or collaborators, Sponsorship Recipient will record the role of Novartis in suggesting, seek other sources and make a final selection based on balance and independence.

2.3 **Disclosure of Financial Relationships.**

- (a) Sponsorship Recipient will: (i) disclose, to all audiences and in all publications relating to the Sponsorship Activity, that Novartis has provided a Sponsorship to support the Sponsorship Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Sponsorship Activity; and (iii) disclose any other

relationships Novartis has with any individual speakers, moderators, collaborators or Sponsorship Recipient which a reasonable and ethical person would expect to be disclosed.

- (b) Novartis may disclose publicly the financial and non-financial support provided to Sponsorship Recipient, including, without limitation, the Sponsorship Recipient's identity, the Sponsorship Amount and purpose of the support.

2.4 **Ancillary Activities.**

- (a) If the Sponsorship Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Sponsorship Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Sponsorship Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Sponsorship Activity is at the sole discretion of Sponsorship Recipient. Meals and/or receptions, if any, will be modest and conducive to the Sponsorship Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.

3. **GENERAL**

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.



IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.

NOVARTIS HEALTHCARE A/S

HUDSAGEN

Date and Signature 1:

Signed by: Malene Skov
Signature: _____
7AA24DAF275A4DA...

Name: Malene Skov

Title: Marketing Manager

Date: 20-Mar-2025 | 6:09:40 AM PDT

Signed by: Bente Willumsen
Signature: _____
37E9EB8AA6A64DC...

Name: Bente Willumsen

Title: Formand, Patientforeningen HS Danmark

Date: 20-mar-2025 | 12:56:23 PM PDT

Date and Signature 2:

DocuSigned by: Mille Holst
Signature: _____
1086847BE9484D4...

Name: Mille Keller Holst

Title: Marketing Director

Date: 20-Mar-2025 | 1:31:15 PM GMT

EXHIBIT A**SPONSORSHIP AMOUNT & SPONSORSHIP ACTIVITY**

Sponsorship Amount: **138.000 kr.** inkl. moms (= 110.400 kr. + moms).

Sponsorship Activity:

In 2025, HudSagen wants to continue the collaboration with Advice and work further with activities targeted at both national and regional decision-makers. In 2025, HudSagen wants to implement the projects 'Painless sector cooperation' and supporting media and PR work. Both parts are to put chronic skin diseases on the agenda and contribute with concrete solutions that improve the quality of life for skin patients throughout Denmark. With pain-free sector cooperation, HudSagen will, among other things,

- Bring together professional representatives from hospitals, specialists and general practitioners to develop cooperation solutions between the sectors, for the benefit of chronic skin patients.
- Publish a publication with recommendations for regional and national politicians.
- Launch the results of the collaboration and present recommendations to decision-makers
- Create media and press coverage of the effort along the way

Evidence must be provided to Novartis upon completion of the Sponsorship Activity:

The Sponsorship amount is payable against the corresponding invoice within sixty (30) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order received by Sponsorship Recipient.

EXHIBIT B**SPONSORSHIP REQUEST LETTER**

Novartis Healthcare A/S
 Edvard Thomsens Vej 14
 2100 København
 Att.: Malene Skov

Søborg, den 14.marts 2025

Anmodning om støtte til HudSagens aktiviteter i 2025: 138.000 kr.

Patientforeningerne "Eksemlforeningen", "Patientforeningen HS Danmark" og "Psoriasisforeningen" står bag alliancen "HudSagen" sammen med sundhedsfaglige eksperter. Alliancens ambition er at inkludere og samarbejde med relevante aktører og eksperter på området og belyse alvorligheden af kroniske hudsygdomme.

HudSagen ønsker i 2025 at fortsætte samarbejdet med Advice og arbejde videre med aktiviteter målrettet både nationale og regionale beslutningstagere. I 2025 ønsker HudSagen at gennemføre projekterne 'Smertefrit sektorsamarbejde' og understøttende medie- og PR-arbejde. Begge dele skal sætte kroniske hudsygdomme på dagsordenen, og bidrage med konkrete løsninger, der forbedrer livskvaliteten for hudpatienter i hele Danmark. Med smertefri sektorsamarbejde vil HudSagen bl.a.

- Samle faglige repræsentanter fra sygehus, speciallæge og praktiserende læger for at udvikle samarbejds løsninger mellem sektorerne, til fordel for kroniske hudpatienter.
- Udkomme med en publikation med anbefalinger til regional- og nationalpolitikere.
- Lancerer samarbejdets resultater og overrække anbefalinger til beslutningstagere
- Lave medie- og pressedækning af indsatsen undervejs.

Vedhæftet er tilbud fra Advice på udarbejdelse af ovenstående. Vi anmoder om støtte, så vi kan tage imod Advices tilbud til i alt 830.200 kr. inkl. moms.

Patientforeningerne er ikke momsregistrerede, hvorfor vi anmoder om beløb inkl. moms. Patientforeningen HS Danmark indgår gerne kontrakt på vegne af HudSagen og fakturerer efterfølgende det aftalte beløb, som så benyttes til at betale Advice. HudSagen anmoder om støtte hos både AbbVie, Almirall, BMS, LEO Pharma, Novartis, Pfizer Sanofi, Takeda og UCB og forventer at opnå støtte fra seks virksomheder.

På vegne af HudSagen anmoder Patientforeningen HS Danmark Novartis om 138.000 kr. til brug for projektet beskrevet i vedhæftede tilbud.

På forhånd mange tak for opbakningen til HudSagens arbejde, og vores gode samarbejde.

Mange hilsner fra HudSagen

Bente Villumsen (Patientforeningen HS Danmark)
Lars Werner (Psoriasisforeningen)
Anne Skov Vastrup (Eksemlforeningen)

Handicaporganisationernes Hus | Blekinge Boulevard 2 | DK-2630 Taastrup
info@hudsagen.dk | www.hudsagen.dk